---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Guidelines questions"
description: "Guidelines questions on Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is the NCCN recommendation for Enhertu in HR-positive HER2-low breast cancer? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/guidelines"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Guidelines questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)

Guidelines questions that apply to every indication of Enhertu are on [Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Guidelines](https://www.evicenter.com/medical-information/enhertu/guidelines).

## Guidelines

<a id="enhertu-nccn-breast-recommendation"></a>

### What is the NCCN recommendation for Enhertu in HR-positive HER2-low breast cancer?

> “NCCN Guidelines recommends fam-trastuzumab deruxtecan-nxki (ENHERTU) for recurrent unresectable (local or regional) or stage IV HER2– breast cancer as a Category 2A, 1L other recommended option for patients with HR-positive disease who are in visceral crisis or are endocrine refractory with tumors that are HER2 IHC 0+, 1+ or 2+/ISH-negative and have no germline BRCA1/2 mutation<sup>7,j-l</sup>”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=NCCN%20Guidelines%20recommends%20fam%2Dtrastuzumab%20deruxtecan%2Dnxki,and%20have%20no%20germline%20BRCA1%2F2)

> “IHC 0+ refers to tumors with faint, partial membrane staining in ≤10% of tumor cells.”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=IHC%200%2B%20refers%20to%20tumors,in%20%E2%89%A410%25%20of%20tumor%20cells.)

> “Assess for germline BRCA1/2 mutations in all patients with recurrent or metastatic breast cancer to identify candidates for PARPi therapy.”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=Assess%20for%20germline%20BRCA1%2F2%20mutations,identify%20candidates%20for%20PARPi%20therapy.)

> “Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Breast Cancer V.4.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed June 12, 2026.”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=Referenced%20with%20permission%20from%20the,reserved.%20Accessed%20June%2012%2C%202026.)

Note: NCCN Guidelines for Breast Cancer V.4.2026, accessed by the manufacturer June 12, 2026, as quoted on the Enhertu HCP site captured November 13, 2026. A later NCCN version may state the recommendation differently.

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/dosing-and-administration)
